GLM showed effectiveness in Japanese rheumatoid arthritis patients with an acceptable safety profile.

Janssen Pharmaceutical K.K. and Mitsubishi Tanabe Pharma Corporation.

No abstract

Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of postmarketing surveillance data, Modern Rheumatology,

Introduction: While dose escalation of golimumab has been used for patients with rheumatoid arthritis who demonstrate an inadequate response to the standard dose, its effectiveness has not been fully evaluated. The aim of this study was to assess the clinical outcome observed by dose escalation of golimumab for patients with rheumatoid arthritis in the daily clinical setting. Methods: A post hoc analysis was performed of data from the 24-week post-marketing